By Novo Nordisk…
To get in touch with Novo Nordisk Pharmatech showcasing human insulin-based production advances at ESACT Copenhagen, simply fill out the form below.
Subscribe to Supplier
Novo Nordisk Pharmatech showcasing human insulin-based production advances at ESACT Copenhagen
Koege, Denmark: – World-leading insulin specialist Novo Nordisk Pharmatech A/S will be a prominent presence at May’s European Society for Animal Cell Technology (ESACT) annual meeting in Copenhagen.
Novo Nordisk Pharmatech will take advantage of the event to highlight its recent breakthroughs in using recombinant animal-free (AF) human insulin to increase Chinese hamster ovary (CHO) cell density and ability to boost virus-like particle (VLP) production by using recombinant Insulin Human AF supplements.
AF insulin supplements
The Danish-based insulin leader will be an exhibitor at ESACT 2019, with a stand at Booths 17-20 at Copenhagen’s Bella Center.
It will also contribute to the scientific agenda with two posters.
The first will focus on ‘Increase viable Sf9 cell density and boost Baculovirus-based VLP production by supplementation with recombinant Insulin Human AF.’
The second will examine: ‘Comparative Study of CHO Cell Culture in Different Media with Insulin Supplementation’.
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. Novo Nordisk Pharmatech A/S is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (quats) for the pharmaceutical, biopharmaceutical industry.
About ESACT 2019
The European Society for Animal Cell Technology (ESACT) as an organization that promotes the communication of knowledge and experience between scientists and engineers whose work has a direct or indirect bearing on cell culture biotechnology and the products derived from it.
ESACT actively encourages interactions between academia, governmental and policy making agencies, and the manufacturing and service industries, such as the international Good Cell Culture Practice (GCCP) Guidance Document.
The 26th ESACT annual meeting is a two-day event opening May 5, 2019 at the Bella Center in Copenhagen. Themed “Cell culture technologies: bridging academia and industry to provide solutions for patients”, the conference will feature numerous scientific presentations, engaging and interactive poster sessions, and a social programme designed to promote interactions and networking, along with pre-meeting satellite events.
The event is organized by ESACT with further information at: http://www.esact2019.com/.